Skip to main content

CND’s Synuclein-One Study Results Published in the Journal of American Medical Association. See the release

Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
April 22, 2024

REM Sleep Behavior Disorder and the Syn-One Test®: The Syn-Sleep Study Explores an Early Warning Sign for Parkinson’s and Related Conditions

On the heels of the highly anticipated publication of the NIH-supported Synuclein-One Study in JAMA,…
Insights
April 9, 2024

Connect to the Syn-One Community Partner Network

“Patients first” is a core value at CND Life Sciences. We understand that behind every…
Insights
March 27, 2024

Top 10 Questions About the Syn-One Test®

If you’re considering implementing the Syn-One Test® in your practice, you probably have several questions…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

On Our Radar
May 22, 2024

Gene-Pesticide Interaction May Increase Risk of Parkinson’s

Genetic mutations and exposure to pesticides have both been identified as risk factors for the…
On Our Radar
May 16, 2024

A Phase 2 Study Suggests Diabetes Treatment May Slow Progression of Motor Symptoms in Parkinson’s Disease

A study published last month in the New England Journal of Medicine evaluated lixisenatide, a…
On Our Radar
May 8, 2024

Tandem Cycling May Improve Health of Patients with Parkinson’s and Their Care Partners

A recent study showed that exercise may be helpful not only for patients with Parkinson’s…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit